返回 Agenda
European Medicines Agencies Network Strategy to 2028: Spotlight on Innovation, Availability & Shortages of Medicines
Session Chair(s)
Melanie Carr
Head of Stakeholders and Communication Division
European Medicines Agency, Netherlands
Aimad Torqui
Head of Division European cooperation and veterinary affairs
MEB, Netherlands
This DIAmond session will update on the status of implementation of the European Medicines Agencies Network Strategy 2025 so far and provide an outlook to 2028 in the areas of innovation, availability of medicines.
Participants will hear from EMA and HMA on the state of play and planned future activities in these two areas, and gain insights on the perspective and expectation of stakeholders including academia, patient representatives and industry.
Speaker(s)
State of Play of the Strategy with Focus on Innovation
Falk Ehmann, MD, PHD, MS
Regulatory Science and Innovation Task Force, European Medicines Agency, Netherlands
Head of Innovation and Development Accelerator
State of Play of the Strategy with Focus on Innovation
Maria Lamas Diaz
AEMPS, Spain
Evecutive Director
State of Play of the Strategy with Focus on Availability of Medicines
Monica Dias, PHARMD, PHD, MPHARM, RPH
European Medicines Agency, Netherlands
Head of Supply and Availability of Medicines and Devices, a.i.
Bjorn Eriksson
Medical Products Agency, Sweden
Panelist
François Houyez
European Organisation for Rare Diseases (EURORDIS), France
Treatment Information and Access Director, Health Policy Advisor
Panelist
Hubert Leufkens, PHARMD, PHD
Utrecht University, Netherlands
Emeritus Professor of Pharmaceutical Policy and Regulatory Science
Panelist
Nathalie Moll
European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
Director General
Panelist
Adrian van den Hoven
Medicines for Europe, Belgium
Director General